SynthesisNature communications2016
Centromere and kinetochore gene misexpression predicts cancer patient survival and response to radiotherapy and chemotherapy.
Synthesis in Nature communications, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 126 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
126 citing papers in PubMed, 195 citations in OpenAlex.
- Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer.JAMA oncology · 2020Trial
- Spindle Assembly Checkpoint Competency Determines Sensitivity to KIF18A Inhibition in Small Cell Lung Cancer.Cancer research communications · 2026Article
- Integrative machine learning and multi-omics identify a centromere gene signature and validate B3GALT4 as a tumor suppressor in osteosarcoma.Journal of bone oncology · 2026Article
- CENP-A in cancer: from centromere identity to genome instability.Molecular biology reports · 2026Review
- Determinants of centromeric nucleosome conformation.bioRxiv : the preprint server for biology · 2026Article
- A genomic and epigenomic view of human centromeres.Nature reviews. Genetics · 2026Review
- Article
- CellMiner cross-database (CellMinerCDB) version 2.2 for explorations of patient-derived cancer cell line pharmacogenomics.Nucleic acids research · 2026Article
- Expression, Prognostic Value, and Biological Function of CENPM in Colon Adenocarcinoma.Current medicinal chemistry · 2026Article
- Non-coding RNAs as regulators of chromosomal instability in breast cancer.Frontiers in oncology · 2026Review
- Cell cycle-related biomarker lineage promotes the malignant progression of recurrent IDH wild-type glioma.Discover oncology · 2025Article
- Pt-seq unveils the genomic binding pattern of platinum-based drugs.Science advances · 2025Article
- CENPT prevents renal cell carcinoma against ferroptosis by enhancing the synthesis of glutathione.Cell death & disease · 2025Article
- Centromere Protein F in Tumor Biology: Cancer's Achilles Heel.Cancer medicine · 2025Review
- Chromosomal Instability and Clonal Heterogeneity in Breast Cancer: From Mechanisms to Clinical Applications.Cancers · 2025Review
- Mutant IDH impairs chromatin binding by PDGFB to promote chromosome instability.bioRxiv : the preprint server for biology · 2025Article
- CENPs in hepatocellular carcinoma: a comprehensive review of expression patterns, clinical correlations, and functional mechanisms.American journal of cancer research · 2025Review
- Protein Phosphatase 1 Regulatory Subunit PNUTS Prevents CENP-A Mislocalization and Chromosomal Instability.Molecular and cellular biology · 2025Article
- CENP-H as a new prognostic biomarker for tumors: a real-world literature review.Frontiers in oncology · 2025Review
- Centromeres in cancer: Unraveling the link between chromosomal instability and tumorigenesis.Medical oncology (Northwood, London, England) · 2024Review
66 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
Abstract
Chromosomal instability (CIN) is a hallmark of cancer that contributes to tumour heterogeneity and other malignant properties. Aberrant centromere and kinetochore function causes CIN through chromosome missegregation, leading to aneuploidy, rearrangements and micronucleus formation. Here we develop a Centromere and kinetochore gene Expression Score (CES) signature that quantifies the centromere and kinetochore gene misexpression in cancers. High CES values correlate with increased levels of genomic instability and several specific adverse tumour properties, and prognosticate poor patient survival for breast and lung cancers, especially early-stage tumours. They also signify high levels of genomic instability that sensitize cancer cells to additional genotoxicity. Thus, the CES signature forecasts patient response to adjuvant chemotherapy or radiotherapy. Our results demonstrate the prognostic and predictive power of the CES, suggest a role for centromere misregulation in cancer progression, and support the idea that tumours with extremely high CIN are less tolerant to specific genotoxic therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.